Navigating the New mRNA Flu Shot: A Discussion With Dr William Schaffner

In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional egg- and cell-based manufacturing, detailing its mechanism of action as a genetic "blueprint" and analyzing the trial data behind its approval for adults aged 50 and older.  Beyond the science, Dr Schaffner offers actionable guidance for health care providers navigating the realities of modern clinical practice. He addresses practical logistics like coadministering mFlusiva alongside routine fall immunizations, including COVID-19, RSV, and pneumococcal vaccines. He also offers empathetic strategies for overcoming vaccine hesitancy, urging clinicians to look beyond technical lectures and focus on patient reassurance and emotional comfort.